Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | MPN Sessions: Key updates from EHA 2022

Claire Harrison, Jean-Jacques Kiladjian and Ruben Mesa • 12 Jun 2022
EHA 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Danazol Fedratinib Momelotinib Navitoclax Pacritinib Pelabresib Ropeginterferon alfa-2b Ruxolitinib
MOMENTUM SURPASS-ET

Welcome to The MPN Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive discussion features leading experts Claire Harrison, Ruben Mesa, & Jean-Jacques Kiladjian, who debate key updates in the treatment and management of myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia, following the 27th Congress of the European Hematology Association (EHA) 2022.

MPN Channel VJHemOnc banner, with Claire Harrison, Ruben Mesa, Lucia Masarova, Naveen Pemmaraju

More from Claire Harrison

Novel agents and approaches being explored in second-line myelofibrosis
14:29
Novel agents and approaches being explored in second-line myelofibrosis
Claire Harrison et al. • 2 Oct 2026
Reflecting on progress in MPN research and care: a lifetime perspective
2:01
Reflecting on progress in MPN research and care: a lifetime perspective
Claire Harrison • 13 Jun 2026
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
3:58
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison • 13 Jun 2026
The Phase III SENTRY trial: selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis
2:41
The Phase III SENTRY trial: selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis
Claire Harrison • 13 Jun 2026

More from Jean-Jacques Kiladjian

12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs
0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care
1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025

More from Ruben Mesa

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
How meaningful benefit in MPNs could evolve over the next five years
2:04
How meaningful benefit in MPNs could evolve over the next five years
Ruben Mesa • 2 Oct 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions
2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026

Related Videos

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals